TOKYO - Takeda Pharmaceutical Co. Ltd. has signed a 10-year joint research program with the Center for iPS Cell Research Application (CiRA) of Kyoto University, under which the main aim is to discover new iPSC-based therapies and progress these into the clinic.
The alliance represents the biggest industry-academic agreement yet focusing on practical applications of the technology, which - together with regenerative medicine in general - has been designated as a key...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?